FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting
US agency is seeking feedback from interested stakeholders about administrative steps it can take to better promote generic competition; July 18 meeting will involve only presentations from the public.
You may also be interested in...
Gottlieb Talks Activist Role For FDA In Curbing REMS Abuse
US FDA commissioner says he would be happy to work with Congress on a legislative solution on the issue, but emphasized his priority is for the agency to develop a system itself to discourage REMS abuse.
REMS Class-Action Lawsuit Against Celgene Is First By Patients
Patients For Affordable Drugs Founder David Mitchell alleges Celgene's unlawful delay tactics like REMS obstruction kept generic versions of Thalomid and Revlimid off the market, forcing plaintiffs to pay higher costs.
Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says
Association for Accessible Medicines report highlights continuing upward trend of cost savings from generic drugs; trade group argues legislative proposals addressing restricted distribution misuse are key to accelerating savings.